LYMPHIR + Pembrolizumab Phase 1 Data Shows 24% ORR, 20.5-Month mPFS in Gynecologic Cancers
CTOR sits 61% above its 52-week low of $0.491 on light trading volume (0.4× avg).
Summary
Citius Oncology presented detailed Phase 1 data for its LYMPHIR + pembrolizumab combination, showing a 24% overall response rate and a median progression-free survival of 20.5 months in responders with recurrent gynecologic malignancies. This positive clinical update, presented at ASCO, provides specific efficacy and durability metrics for a key pipeline asset. The news is particularly important as the company has recently faced a Nasdaq delisting notice and going concern doubts, making strong clinical validation critical for its future.
At the time of this announcement, CTOR was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.7M. The 52-week trading range was $0.49 to $6.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.